Targeting glycans for cancer immunotherapy
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
Nature Biotechnology, published online: December 16, 2025; doi:10.1038/s41587-025-02924-1
Antibody-lectin chimeras (AbLecs) are an immunotherapy modality designed to bind and block glycans that contribute to immune suppression in cancer. AbLecs enhance anti-tumor immune responses in vitro and in vivo, outperforming conventional antibody therapies, including approved anti-cancer drugs.
